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Abstract
Objective: Estimate the prevalence of psychotropic drugs use in the city of Rio de Janeiro, Brazil, and establish its
relationship with the presence of mental disorders.
Methods: A probabilistic sample of non-institutionalized individuals, from the general population of Rio de Janeiro
(n = 1208;turn out:81%), 15 years or older, who were interviewed using the Composite International Diagnostic Interview 2.1
(depression, anxiety-phobia, OCD\PTSD, alcoholism sections), and asked about their psychotropic use during a 12 and one-
month period before the interview. Data were collected between June/2007-February/2008.The prevalence was estimated
with a confidence interval of 95%. The associations between psychotropics use and mental disorders were analyzed through
a logistic regression model (Odds Ration – OR).
Results: The one-month prevalence of psychotropic drug use was 6.55%, 3.19% for men and 9.13% for women.
Antidepressants were the most frequently used drug (2.78%), followed by anorectics (1.65%), tranquilizers (1.61%) and
mood stabilizers (1.23%). General practitioners issued the highest number of prescriptions (46.3%), followed by psychiatrists
(29.3%); 86.6% of the psychotropic drugs used were paid for by the patient himself. Individuals with increased likelihood of
using psychotropic drugs were those that had received a psychiatric diagnosis during a one-month period before the study
(OR:3.93), females (OR:1.82), separated/divorced (OR:2.23), of increased age (OR:1.03), with higher income (OR:2.96), and
family history of mental disorder (OR:2.59); only 16% of the individuals with a current DSM IV diagnosis were using a
psychotropic drug; 17% among individuals with a depression-related diagnosis and 8% with Phobic Anxiety Disorders-
related diagnosis used psychotropics.
Conclusion: Approximately 84% of individuals displaying some mental disorder did not use psychotropic drugs, which
indicates an important gap between demand and access to treatment. A significant failure is evident in the health system
for patients with mental disorders; this could be due to health workers’ inability to recognize mental disorders among
individuals.
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Introduction
The prevalence of psychotropic drug use in the general
population varies greatly between countries: 3.5% in England
[[1], 6.4% in Chile [2], 7.2% in Canada [3], and 10.6% in
Australia [4]. The European Study of the Epidemiology of Mental
Disorders/Mental Health Disability: a European Assessment
(ESEMed/MHEDEA 2000) [5], performed in six European
countries (Belgium, France, Germany, Italy, the Netherlands
and Spain), estimated an annual prevalence of 12.3%. The
Medical Expenditure Panel Survey (MEPS) in the US reported
annual prevalences of 5.9% in 1996, 7% in 2000, and 8.1% in
2001 [6]. According to the National Health and Nutrition
Examination Surveys (NHANES) carried out between 1988 and
1994 [7] and 1999 and 2002 [8], the consumption of psychotropic
drugs in the American population increased from 6.1% to 11.1%.
An epidemiological study carried out in Rio de Janeiro by
Almeida et. al. [9] in 1988 in the Governador Island county,
estimated a prevalence of 5.2% in psychotropic use. At the
beginning of the 90s, Mari et al. reported a 12-month prevalence of
10.2% for 4 districts in the city of Sa˜o Paulo [10], and in 1994
Lima et al. [11] found an 12-month prevalence of 9.9% in the
South of Brazil, among a population of 328,000 inhabitants.
Although a diagnosis of mental disorder increases the chance of
using psychotropic drugs, the existence of a gap between demand
and use of these drugs is noteworthy because this difference can
reach 80% [5]. Women of older age and with high income are the
main users of these drugs [3,5,8,10].
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The primary objectives of this study were to estimate the
prevalence of psychotropic use in the city of Rio de Janeiro and
the factors associated with this use, with emphasis on the presence
of mental disorders. The secondary objectives were to identify the
main prescribers and clarify how these medications were more
frequently obtained.
Methods
Settings and study design
The present study was based on data from a larger project titled
‘‘Violence and post-traumatic stress disorder in Sa˜o Paulo and Rio
de Janeiro, Brazil.’’ The detailed study protocol is available in an
open-access online journal [12]. A population-based cross-
sectional survey was carried out in Rio de Janeiro, Brazil, between
June 2007 and February 2008. The sample was representative of
the population and included individuals older than 15 years old.
The city was initially stratified into seven areas according to
homicide rates (index of violence). Subsequently, 30 households
per census sector were randomly selected within each stratum.
Finally, one resident in each selected household was randomly
selected to be interviewed according to Kish’s method [13].
Ethics Statement
This study was approved by the ethical committee of the
Federal University of Sao Paulo (process n. 1369/04).
Measurements
The socio-demographic variables were collected using a
questionnaire specifically designed for the study. The variables
of interest in this analysis were gender, age, marital status, formal
education, income, ethnic group, history of migration, and family
history of mental illness; the clinical variable was psychiatric
diagnosis one-month prior to the study (CIDI 2.1 DSM IV).
We used the 2.1 version of the Composite International
Diagnostic Interview to assess mental disorders (anxiety, depressive
disorders, and alcohol misuse/dependence). The CIDI 2.1 is a
standardized and fully structured interview that provides psychi-
atric diagnoses through computerized algorithms according to the
Diagnostic and Statistical Manual of the American Psychiatric
Association, 4th edition (DSM-IV). The Portuguese version of the
CIDI 2.1 has been previously validated and adapted to Brazil’s
social and cultural context [14–16].
Participants were asked the following question: ‘‘Have you taken
any medication for a nervous breakdown, emotional, psycholog-
ical, or psychiatric problems, or seizures in the last year?’’
Individuals who provided a positive answer were subsequently
questioned about the use of the drug in the last month, the type of
medication, who prescribed it, and where the medication was
obtained. Information cards, containing information about generic
and trade psychotropic drug names available in the Brazilian
market, medical specialties, health professionals, and ways to
obtain medications were presented to the respondent. The
psychotropic drugs were primarily classified by their pharmaco-
logical group, taking into account their main clinical indications.
Procedures
Face-to-face interviews were performed by a team of lay
interviewers provided by the Brazilian Institute of Public Opinion
and Statistics (www.ibope.com.br), which is one of the largest
Brazilian independent research institutes. The interviewers were
trained by researchers from an official CIDI\WHO\UNIFESP
Training Center to apply the CIDI. The interviewers were trained
by the authors to apply the full set of questionnaires used in the
study. To optimize response rates, interviewers visited the selected
households up to ten times.
Statistical analysis
Statistical Package for the Social Sciences 19 (SPSSH) was used.
The prevalence of psychotropic use and mental disorders was
estimated within confidence intervals of95%. The analysis was
adjusted for the complex sample design effect. We focused on
psychotropic use and psychiatric diagnosis one month before the
study. We used a chi-square test to detect statistically significant
associations between the socio-demographic variables and access
to medication.
Logistic models were fitted to investigate associations between
use of psychotropic drugs, socio-demographic and clinical
variables. The first model included variables with p,0.10 from
the univariate analysis. The first stage of the modeling process
included all variables with p,0.10 from the univariate analysis. In
the second stage, variables which p-values became larger than 0.05
were dropped from the model, except for the variable education.
Both used the enter method of entry. As shown by Pearce [17] and
Reichenheimand & Coutinho [18], the exponential of the logistic
regression coefficient can estimate the incidence density ratio
(IDR) when the following conditions are met: a) the population is
in a steady state during the study period (stationary), i.e., the size of
the population is constant across the psychotropic users and non
users; b) no selective survival is allowable, i.e., the probability of
withdrawal or death from the outcome under this study or other
related causes is probably not different across users and non-users;
c) the exposure does not seem to influence the survival or recovery
probabilities; d) reverse causality is not likely, i.e., the outcome
being modeled is not a reciprocal cause on the exposure status;
and e) the temporal directionality, from the exposure to the
outcome, is sustainable either theoretically or by means of a
thorough data collection procedure.
Results
Interviews were obtained with 1208 respondents (an overall
response rate of 81.6%), 56.6% of the participants were women
(15–75 years; M:42 years, SD: 16.12), 52.4% living with a partner
(52.4%). Fifty-three percent were blacks or mulattos, 69% were
natives of Rio de Janeiro, with an average of 9.75 years of school
attendance and 27% reported history of mental illness in the
family. Sixty-eight percent reported family income of less than
US$ 477 per month, 89% were employed at the time of the study
(Table 1).
The only significant difference between non-users and users of
psychotropic drugs was average age (41 and 49 years old,
respectively; p,0.001, Table 1).
The prevalence of psychotropic drug use was 6.55% (n = 82)
and three times higher among women (Table 2). Antidepressants
were the most widely used psychotropic drugs (2.78%), especially
second-generation psychotropics (2.36%). Women consumed
more antidepressants than men (3.65% vs. 0.67%, p,0.001).
The second most consumed category of psychotropic drugs was
anorectics (1.65%), followed by tranquilizers (1.61%), mood
stabilizers (1.24%), and antipsychotics (1.05%). Hypnotics, anti-
cholinergics, barbiturates, medications for treating alcoholism, and
others were taken by less than 1% of the studied group. Although
point estimates of the various types of drugs were higher in females
than males, these differences only showed statistical significance in
the case of antidepressants.
More than half of the psychotropic users (67.1%; n = 55) used
only one psychotropic drug during the month previous to the
Epidemiology of Psychotropic Use in Rio de Janeiro
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Table 1. Distribution of the sample’s socio-demographic features (n = 1,208) and prevalence of the use of psychotropic drugs in




Prevalence ofpsychotropic drug use
% (IC 95%)
Psychotropic consumption 6.55 (5.05–8.06)
Gender
Male 524 (43.5) 3.19 (1.72–4.65)
Female 684 (56.5) 9.13 (6.74–11.52)
Age (years)
15–19 100 (8.3) 0.77 (0–1.85)
20–29 221(18.3) 1.17 (0–2.59)
30–39 247(20.4) 8.15 (4.39–11.92)
40–49 232(19.2) 5.81(2.58–9.03)
50–59 206(17.1) 12.54 (7.42–17.67)
60–69 135(11.2) 8.06(3.48–12.63)
70–75 67(5.5) 8.55 (1.43–15.67)
Marital status
married/living with a partner 633 (52.4) 5.96 (3.90–8.01)
widow/er 71 (5.9) 10.42 (2.22–18.62)
separated/divorced 129 (10.7) 13.51 (7.17–19.85)
single 375 (31.0) 4.42 (2.39–6.44)
Employed
No 87 (11.1) 8.68 (6.00–11.36)
Yes 699 (88.9) 4.91 (3.23–6.59)
Education
Illiterate 19 (1.6) 2.09 (0–6.23)
4 years 154 (12.7) 7.96 (3.58–12.34)
8 years 284 (23.5) 5.25 (2.31–8.19)
11 years 384 (31.8) 5.43 (2.93–7.92)
.12 years 367 (30.4) 8.32 (5.30–11.33)
Native of
RJ 831 (68.8) 6.62 (4.80–8.44)
Others 377 (31.2) 6.40 (3.70–9.11)
Religion
Catholic 656 (54.7) 5.52 (3.66–7.38)
Evangelical 298 (24.8) 6.89 (3.72–10.06)
Spirit 105 (8.8) 7.89 (2.29–13.48)
Atheist 26 (2.2) no observations
Others 29 (2.4) 12.61 (0–25.60)
Religious 86 (7.2) 10.23 (3.49–16.97)
Race
White 515 (42.7) 8.20 (5.60–10.80)
Black/mixed 643 (53.4) 4.27 (2.70–5.83)
Others 47 (3.9) 17.12 (4.14–30.10)
Family income
,159 US$ 214 (18.6) 3.61 (0.90–6.32)
160–272 US$ 270 (23.4) 5.90 (2.60–9.20)
273–476 US$ 301 (26.1) 6.43 (3.39–9.47)
.477 US$ 367 (31.9) 8.75 (5.83–11.67)
Family history of mental illness
No 880 (72.8) 93.45 (91.94–94.95)
Yes 328 (27.2) 6.54 (5.05–8.06)
doi:10.1371/journal.pone.0062270.t001
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study, 20.7% (n = 17) used two, and 12.2% (n = 10) used three or
more.
The main prescribers were general practitioners (46.3%)
followed by psychiatrists (29.3%), cardiologists and neurologists
(9.8%), and other doctors (4.9%). The observation that some of the
psychotropic drugs were provided by non-medical professionals
such as psychologists, dentists, pharmacists, priests, pastors,
friends, relatives, and others (11.0%) was a noteworthy finding
of this study. Majority of the individuals (86.6%) obtained the
drugs with their private resources, 3.7% was given by friends or
family and 9.8% through government programs. The classes of
psychotropic drugs acquired free of charge through government
programs were: antipsychotics (7.7%), antidepressants (8.1%), and
tranquilizers (15.4%).
A total of 84% of individuals had at least one one-month mental
disorder confirmed by the CIDI and did not use psychotropic
drugs. This prevalence was also high in individuals with depressive
disorder (72.9%) and phobic anxiety disorder (85.6%) (Table 3).
The investigation of the associations between the socio-
demographic and clinical variables and psychotropic drug use
through multivariate models revealed a positive association with
the female gender, increased age, marital status (separated or
Table 2. Prevalence of the use of psychotropic drugs, during one month, in the city of Rio de Janeiro, distributed by drug type and
gender.
Male (n=524) Female (n=684) Total (n = 1208)
% IC95% % IC95% % IC95%
Psychotropic(general)* 3.19 1.72–4.65 9.14 6.74–11.52 6.55 5.05–8.06
Antidepressive* 1.08 0.19–1.97 4.08 2.47–5.69 2.78 1.79–3.77
1a generation 0.41 0–0.97 0.74 0–1.49 0.59 0.10–1.08
2a generation 0.67 0–0.14 3.65 2.16–5.15 2.36 1.46–3.26
Tranquilizers 1.04 0.18–1.89 2.04 0.76–3.33 1.61 0.79–2.42
Anorectics 0.80 0.10–1.50 2.30 1.01–3.59 1.65 0.86–2.44
Mood stabilizers 0.67 0–1.35 1.67 0.59–2.76 1.24 0.55–1.92
Antipsychotics 0.80 0.01–1.56 1.26 0.42–2.09 1.05 0.47–1.63
typical 0.80 0.02–1.56 1.09 0.32–1.87 0.96 0.41–1.51
atypical 0 0 0.16 0–0.47 0.09 0–0.27
Hypnotics* 0 0 0.40 0–0.97 0.22 0–0.55
Anticholinergics 0.38 0–0.91 0 0 0.17 0–0.40
Barbiturates 0.07 0–0.22 0 0 0.03 0.03–0.10
Alcoholism treatment 0 0 0.16 0–0.47 0.09 0–0.27




Table 3. Frequencies in the use of psychotropics distributed by type of drug and diagnosis identified in the month previous to the









Depression 48 6.3 (3) 16.7 (8) 72.9 (35)
Light depression 20 - 15.0 (3) 70.0 (14)
Moderate depression 12 8.3 (1) 16.7 (2) 75.0 (9)
Severe depression 9 22.2 (2) 22.2 (2) 66.7 (6)
Dysthymia 7 - 14.3 (1) 85.7 (6)
Anxiety-phobias 118 2.5 (3) 7.6 (9) 85.6 (101)
TOC 27 - 7.4 (2) 81.5 (22)
PTSD 28 - 3.6 (1) 71.4 (20)
Any of the above 262 3.4 (9) 6.9 (18) 84.0 (220)
GAP: individuals with positive diagnosis by the CIDI who did not receive psychotropic medication; TOC: Obsessive Compulsive Disorder; PTSD: Post-Traumatic Stress
Disorder.
doi:10.1371/journal.pone.0062270.t003
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divorced), psychiatric illness diagnosed in the month previous to
the study, family history of mental illness, and belonging to the
group with the highest family income range (Table 4).
The distribution of psychotropic use was similar between the
12-month and one-month in the study. The total consumption
prevalence for 12-month was 11.2% (n = 136). The most
consumed drugs were antidepressants (4.60%), anorectics, mood
stabilizers, tranquillizers, and antipsychotics. There were genders
differences in the prevalence of use of anti-depressants and
hypnotics (Table 5).
Over a 12-month period, the odds ratio for diagnosis was 4.21
(IC: 2.79–6.35, p,0,001). The magnitude of the remaining
associations showed no significant changes.
Discussion
This is a report on the associations between the use of
psychotropic drugs and presence of various mental disorders in
residents in the city of Rio de Janeiro aged 15 and over. The use of
psychotropic drugs was 6.55% in a one-month period and the
most-used drug class was antidepressants. Variables such as age,
female gender, being separated/divorced, having higher income
and higher education, mental illness diagnosed in the last year,
and family history of mental disorder were independently
associated with use of psychotropic drugs in a one-month period
of the study. The general practitioners were the main prescribers,
the majority of participants in the study paid for the medication
themselves, and 84% of the individuals with mental illness in a
one-month period, as confirmed by the CIDI 2.1, did not use
psychotropic drugs.
The one-month prevalence of psychotropic medication use
observed in this study is similar to those found in reports in Chile
(6.4%) [2], Spain (6.9%) [19], Canada (7.2%), and USA (5.5%)
[7]. However, they were higher than reported in England (3.5%)
[1] and lower than reported in Australia (10.6%) [4] as well as
southern Brazil (9.9%) [20].The annual consumption prevalence
was 11.2%, which was higher than reported in the Netherlands
(7.4%) [5] and Germany (5.9%) [5], and lower than reported in
France (19.2%) [5], Spain (15.5%) [5], Italy (13.7%) [5], and
Belgium (13.2%) [5].
The highest use of psychotropic drugs occurred among women
and was associated with increased age and income, which agrees
with other epidemiological surveys [3,5,7,21,22]. Women tend to
present higher prevalence of affective disorders, such as anxiety
and depression, seek health services more frequently, and show
emotional symptoms with greater ease, if compared to men
[5,23,24]. Alcoholism, which is more frequent in the male
population, is inversely associated with use of psychotropic drugs
(5). Aparasu et al. [25] state that individuals who grow old in good
physical health tend to use less psychotropic substances. The
negative perception of decreased health status with aging [26,27],
loss of skills, presence of organic chronic diseases leading to an
increase in depressive/anxiety episodes, and difficulty sleeping
[28] are the factors most commonly associated with increased use
of psychotropic drugs with age.
Antidepressants were the most used drugs, primarily among
women. The prevalence reported in studies performed since 2000
are similar to the ones reported in the present study and range
from 1% in the European study by Ohayon [29], to 6.8% in Chile
[2] and Australia [4], and 8.4% in Brazil in 1994 [30]. There has
been an increase in use of antidepressants, especially the Selective
Serotonin Reuptake Inhibitors (SSRIs) [21,25,31]. Zuvekas report
a gradual increase in the use of psychotropic drugs from 5.9% in
1996 to 8.1% in 2001, in the US, where the SSRI and other new
antidepressants account for 80% of this increase [6].
Table 5. Prevalence of psychotropic drug use during one





% IC95% % IC95% % IC95%
Psychotropic
(general)*
6.56 4.26–8.86 14.72 11.76–17.68 11.18 9.21–13.14
Antidepressive* 1.67 0.56–2.79 6.83 4.70–8.97 4.60 3.28–5.90
1a generation 0.61 0–1.31 1.17 0.19–2.15 0.99 0.30–1.56
2a generation 1.06 0.18–1.93 5.98 4.01–7.95 3.84 2.65–5.03
Anorectics 1.53 0.31–2.76 3.91 2.21–5.60 2.88 1.78–3.98
Mood stabilizers 1.03 0.04–2.02 2.32 1.02–3.61 1.76 0.91–2.61
Tranquilizers 1.04 0.18–1.89 2.30 0.98–3.62 1.75 0.92–2.59
Antipsychotics 0.79 0.02–1.56 1.75 0.70–2.86 1.33 0.65–2.02
typical 0.79 0.02–1.56 1.59 0.59–2.60 1.24 0.58–1.90
atypical 0 0 0.44 0–1.08 0.25 0–0.61
Others 1.58 0.55–2.61 2.20 1.07–3.33 0.84 0.40–1.29
Anticholinergics 0.75 0–1.64 0 0 0.33 0–0.71
Barbiturates 0.07 0–0.22 0.44 0–1.08 0.28 0–0.64
Alcoholism treatment 0.37 0–1.07 0.22 0–0.55 0.28 0–0.65
Hypnotics* 0 0 0.40 0–0.97 0.22 0–0.55
Attention Deficit 0 0 0.57 0–0.17 0.03 0–0.10
*p,0.001.
doi:10.1371/journal.pone.0062270.t005
Table 4. Parameter estimates for simultaneous effects of
gender, age, education, marital status, race, religion, family
income, diagnosed by the CIDI 2.1 (1 month), and family
history of mental illness on psychotropic consumption in the
month of the study (n = 1208).
Odds
Ratio Sig. 95% CI
Lower Upper
Sex (female) 1.82 0.03 1.048 3.175
Age 1.03 0.003 1.009 1.048
Education (years) 0.99 0.76 .932 1.052
Marital status
married Reference
single 0.97 0.95 .386 2.446
separated\divorced 2.23 0.01 1.167 4.262
widow/er 1.43 0.26 .768 2.657
Family mental illness 2.59 0.001 1.587 4.228
Family income .
,160 Reference
160–272 US$ 1.79 0.21 .716 4.464
273–476 US$ 1.95 0.14 .801 4.737
.477 US$ 2.96 0.02 1.197 7.297
CIDI diagnosis (positive) 3.93 0.001 2.372 6.512
Constant 0.002 0.000
doi:10.1371/journal.pone.0062270.t004
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The consumption prevalence observed in this study for
tranquilizers was similar to that described in Australia (1.8%)
[4]; however, it was lower than the 3.3% prevalence reported by
Galduro´z, who evaluated 107 Brazilian cities in 2001 [32] and the
7.6% observed in the Rio Grande do Sul, a Southern state in
Brazil, in 1994 [33]. This reduction in the use of tranquilizers
might be related to an increase in the number of prescriptions for
the use of antidepressants for psychiatric and clinical disorders
[25,26,34,35].
The main sources of prescription of psychotropic substances
were general practitioners, followed by psychiatrists. In a study by
Mari et al. in 1989 [21], general practitioners accounted for 46.9%
of the issued prescriptions and psychiatrists for only 11.7%. In
Brazil, Almeida et al. [9] observed that 65.8% of the prescriptions
were written by general practitioners in Rio de Janeiro in 1994,
whereas in Rio Grande do Sul this percentage was 41% [30]. In
England (1) and Norway (2), 80% of the prescriptions for
psychotropic drugs were written by general practitioners and only
5.0% by psychiatrists. A possible explanation for the increase in
psychotropic drugs prescribed by psychiatrists could be the trend
of increasing specialization and increased number of specialized
professionals in the market.
We found that only 16% of the individuals with a one-month
diagnosis were using psychotropic medication, a situation which is
also described by other authors. In Canada, this rate is reported as
19.3% [3], 15.9% in the UK [1], and 32.6% in a multicenter
European study [5]. In our sample, only 19% of the subjects
diagnosed with moderate to severe depression used antidepres-
sants. Ohayon et al. [1] reported in a study in England that 10–
40% of individuals with psychiatric diagnosis received a psycho-
tropic drug and only 35% of individuals with depression received
some type of treatment with psychotropic drugs; 20% among these
used antidepressants. The recognition of the disease by a
professional does not guarantee that patients will indeed receive
adequate treatment; other studies report that only about 40% will
receive appropriate medication and among these, non-adherence
may still occur [36,37].
In the European Study of Epidemiology of Mental Disorders
[5], which evaluated diagnosis and medication use during one year
in a sample of 21,425 individuals, the proportion of individuals
diagnosed with depression who received antidepressants was
21.1%. Of these, 4.6% used only antidepressants and 18.4% used
only benzodiazepines. As expected, the frequencies of psychotro-
pic drug use increased with the severity of the disorder.
Drug treatment for anxiety-phobias occurred in 8% of the cases
diagnosed by the CIDI 2.1. In this dataset, exclusive use of
benzodiazepines was higher than any other drug for some
disorders like agoraphobia, social phobia, and panic disorder.
Despite the increased access to specialists, in most cases patients
did not receive the first-choice medication, which would be
antidepressants. This finding is worrisome because inadequate
drug-based treatment might cause chronification of symptoms,
long-term use of the drug, and consequently drug dependency
[38].
Some limitations in this study should be taken into account: a)
only diagnoses of depressive disorders, phobic disorders-anxiety,
and alcoholism were investigated; b) the diagnoses were carried
out through a standardized instrument with all the inherent
limitations of the method; c) possible bias in the participants’
responses due to difficulty in remembering the drugs used within
the last year, or mistaking the commercial names of the drugs in
the Brazilian market; d) individuals might have received a
prescription and did not follow treatment; e) the diagnosis does
not determine the use of medication; disorders with milder/
moderate symptoms do not necessarily have to be treated with a
psychotropic drug, and these would be false positive cases in the
treatment gap; and f) the use of homeopathic drugs or herbal
medicines that are often used as tranquilizers was not included in
this study.
Comparisons with other studies must be made with caution
considering that methodologies could be significantly different. For
example, the investigation of psychotropic use is often facilitated
by the use of visual material such as photographs, while others
studies accepted information provided by family members.
Moreover, the investigated period can vary widely (lifetime, 12-
month, one-month, or current). Other possible reasons include
differences in the historical period in which the data were collected
(time frame).
To sum up, a large number of individuals with some mental
disorder did not use psychotropic drugs, either because they did
not seek help and/or because health professionals did not identify
their symptoms as a relevant clinical problem. The results of this
study show that even though the number of new professionals in
the recent years has increased and social conditions in the country
have improved, many individuals with mental disorders are not
receiving pharmacological treatment.
Higher income was associated with increased consumption of
these drugs. The lack of financial coverage to obtain the
medication among the socially underprivileged could explain
lower consumption within this group. The identification of the
barriers associated with receiving health care, and a better
understanding of the stigma related to seeking treatment for
mental disorders are imperative to improve the treatment of
mental illnesses.
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